ClinicalTrials.gg
Sign In
CompletedNCT01991483Updated Mar 7, 2019Results posted

A Study of LY2928057 in Hemodialysis Participants

A Phase 1 interventional study of LY2928057 and Placebo in Renal Insufficiency, Chronic and Kidney Disease, Chronic, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in hemodialysis participants. This study will involve multiple doses of LY2928057 given during a 6 week period either after a participant discontinues or reduces treatment to stimulate red blood cells. This study will last up to 26 weeks for each participant.

02

Conditions studied

  • Renal Insufficiency, Chronic
  • Kidney Disease, Chronic
03

In context

Renal Insufficiency, Chronic

3,224 studies on the registry are indexed under Renal Insufficiency, Chronic; 706 are open to participants now.

This study's enrollment of 28 is below the median of 74 across 2,229 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,095 studies on the registry; 142 are open to participants now.

Of its 535 completed or terminated interventional studies of FDA-regulated products, 356 (67%) have results posted.

Browse Eli Lilly and Company studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants having end-stage renal disease (ESRD), have received an erythropoiesis stimulating agent (ESA) at least weekly for 2 weeks prior to screening, and have been receiving adequate maintenance hemodialysis (3 times weekly) for at least 12 weeks prior to screening (that is, an approximate Kt/V greater than 1.1 (K equals dialyzer clearance of urea, t equals dialysis duration time, V equals volume of distribution of urea, which is approximately equal to the participant's total body water) based on the clinical judgment of participant's nephrologist and investigator and who are willing to stop (Parts A and B) or reduce (Part C) their stable ESA dose from the week of randomization until completion of the 6-week treatment period (unless rescue therapy is needed)
  • Have a hemoglobin value (taken prior to dialysis if taken on a dialysis day) greater than or equal to 9.5 grams per deciLiter (g/dL) and less than or equal to 12.5 g/dL at screening
  • Have a body mass index (BMI) of 18.5 to 45 kilograms per square meter (kg/m\^2) inclusive at screening
  • Have a transferrin saturation (TSat) greater than or equality to 15 percent and ferritin greater than 40 nanograms per milliliter (ng/mL) at screening

Exclusion criteria

Exclusion Criteria:

  • Any cause of anemia other than renal disease
  • A history of hyporesponsiveness to ESA
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    LY2928057 (No ESA)

    Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.

    Drug: LY2928057

  • Experimental
    LY2928057 (Reduced ESA)

    Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.

    Drug: LY2928057

  • Placebo comparator
    Placebo (No ESA)

    Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.

    Drug: Placebo

  • Placebo comparator
    Placebo (Reduced ESA)

    Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.

    Drug: Placebo

Interventions

  • DrugLY2928057

    Administered intravenously

  • DrugPlacebo

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of other nonserious adverse events (AEs) and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline to Study Completion (up to Day 137)

  2. Change From Baseline in Hemoglobin at 6 Week Endpoint

    Time frame: Baseline, Day 42

Secondary outcomes

  1. Pharmacodynamics (PD): Maximum Change in Hemoglobin

    Time frame: Baseline through 6 Weeks

  2. Pharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations Relative to Baseline

    Pharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations relative to baseline.

    Time frame: Baseline, 6 weeks

  3. Pharmacodynamics (PD): Maximum Change in Transferrin Saturation (TSat)

    Time frame: Baseline through 6 weeks

  4. Pharmacodynamics (PD): Maximum Change in Concentration of Hemoglobin in Reticulocytes (CHr)

    Time frame: Baseline through 6 weeks

  5. Pharmacodynamics (PD): Maximum Change in Reticulocyte Count

    Time frame: Baseline through 6 weeks

  6. Pharmacodynamics (PD): Maximum Change in Red Blood Cell (RBC) Count

    Time frame: Baseline through 6 weeks

  7. Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Volume (MCV)

    Time frame: Baseline through 6 weeks

  8. Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin (MCH)

    Time frame: Baseline through 6 weeks

  9. Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin Concentration (MCHC)

    Time frame: Baseline through 6 weeks

  10. Pharmacodynamics (PD): Maximum Change in Ferritin

    Time frame: Baseline through 6 weeks

  11. Pharmacokinetics: Maximum Concentration (Cmax) of LY2928057

    Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2 days (d), 4d, 7d, 9d, 11d postdose; Time frame for Cycle 3: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d, 14d postdose

    Time frame: Cycle 1: Predose, end of infusion, 2hours(h), 4h, 2d, 4d, 7d, 9d, 11d postdose;

  12. Pharmacokinetics: Area Under the Concentration Curve From Time Zero to Infinity (AUC[0-inf]) of LY2928057

    Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d postdose; Time frame for Cycle 3: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d, 14d postdose;

    Time frame: Cycle 1: Predose, end of infusion, 2hours(h), 4h, 2d, 4d, 7d, 9d, 11d postdose

  13. Number of Participants With Anti-LY2928057 Antibodies

    Time frame: Baseline through 84 days

  14. Area Under the Plasma Concentration-Time Curve From 0 to 336 Hours AUC(0-336) During and Outside Dialysis

    Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d postdose; Dialysis did not occur in cycle 1.

    Time frame: Cycle 1: Predose, end of infusion, 2hours, 4h, 2d, 4d, 7d, 9d, 11d postdose

07

Results

Posted Feb 7, 2019

Participant flow

Dose Level: Placebo
Participant flow — Dose Level: Placebo
MilestonePlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Started7000
Received at least one dose of study drug7000
Completed7000
Not completed0000
Dose Level 300 mg
Participant flow — Dose Level 300 mg
MilestonePlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Started0600
Received at least one dose of study drug0600
Completed0600
Not completed0000
Dose Level 600 mg
Participant flow — Dose Level 600 mg
MilestonePlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Started00110
Receive at least one dose of study drug00110
Completed0090
Not completed0020
Withdrew: Withdrawal by subject0010
Withdrew: Physician decision0010
Dose Level 1000 mg
Participant flow — Dose Level 1000 mg
MilestonePlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Started0004
Received at least one dose of study drug0004
Completed0003
Not completed0001
Withdrew: Protocol violation0001

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of other nonserious adverse events (AEs) and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline to Study Completion (up to Day 137)
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0000
PrimaryChange From Baseline in Hemoglobin at 6 Week Endpoint
Time frame:
Baseline, Day 42
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline in Hemoglobin at 6 Week Endpoint
grams per deciliter (g/dL)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Change From Baseline in Hemoglobin at 6 Week Endpoint-1.674 ± 0.5535-1.739 ± 0.5261-0.906 ± 0.4577-1.623 ± 1.0469
SecondaryPharmacodynamics (PD): Maximum Change in Hemoglobin
Time frame:
Baseline through 6 Weeks
Reported as:
Mean · millimoles per liter of iron (mml/L-Fe)
Pharmacodynamics (PD): Maximum Change in Hemoglobin
millimoles per liter of iron (mml/L-Fe)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Hemoglobin1.294 ± 0.3201.677 ± 0.7011.162 ± 0.3671.348 ± 0.563
SecondaryPharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations Relative to Baseline

Pharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations relative to baseline.

Time frame:
Baseline, 6 weeks
Reported as:
Geometric mean · Ratio
Pharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations Relative to Baseline
RatioPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Geometric Mean Ratio of Serum Iron (Fe) Concentrations Relative to Baseline0.99 ± 161.57 ± 321.59 ± 692.36 ± 44
SecondaryPharmacodynamics (PD): Maximum Change in Transferrin Saturation (TSat)
Time frame:
Baseline through 6 weeks
Reported as:
Mean · percentage change in TSat
Pharmacodynamics (PD): Maximum Change in Transferrin Saturation (TSat)
percentage change in TSatPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Transferrin Saturation (TSat)0.2117 ± 0.11200.5250 ± 0.08730.5000 ± 0.15500.4375 ± 0.0624
SecondaryPharmacodynamics (PD): Maximum Change in Concentration of Hemoglobin in Reticulocytes (CHr)
Time frame:
Baseline through 6 weeks
Reported as:
Mean · picograms (pg)
Pharmacodynamics (PD): Maximum Change in Concentration of Hemoglobin in Reticulocytes (CHr)
picograms (pg)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Concentration of Hemoglobin in Reticulocytes (CHr)1.93 ± 0.453.00 ± 1.183.60 ± 2.313.20 ± 1.45
SecondaryPharmacodynamics (PD): Maximum Change in Reticulocyte Count
Time frame:
Baseline through 6 weeks
Reported as:
Mean · gigaparticles per liter (GI/L)
Pharmacodynamics (PD): Maximum Change in Reticulocyte Count
gigaparticles per liter (GI/L)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Reticulocyte Count49 ± 37.672.17 ± 29.2140.73 ± 13.8174.25 ± 78.73
SecondaryPharmacodynamics (PD): Maximum Change in Red Blood Cell (RBC) Count
Time frame:
Baseline through 6 weeks
Reported as:
Mean · tera per liter (TI/L)
Pharmacodynamics (PD): Maximum Change in Red Blood Cell (RBC) Count
tera per liter (TI/L)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Red Blood Cell (RBC) Count0.686 ± 0.1350.900 ± 0.3410.627 ± 0.2280.725 ± 0.299
SecondaryPharmacodynamics (PD): Maximum Change in Mean Corpuscular Volume (MCV)
Time frame:
Baseline through 6 weeks
Reported as:
Mean · femtoliters (fL)
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Volume (MCV)
femtoliters (fL)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Volume (MCV)5.9 ± 4.65.2 ± 1.96.2 ± 1.77.0 ± 3.2
SecondaryPharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin (MCH)
Time frame:
Baseline through 6 weeks
Reported as:
Mean · femtomoles of iron (fmol[Fe])
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin (MCH)
femtomoles of iron (fmol[Fe])Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin (MCH)0.107 ± 0.0290.105 ± 0.0270.091 ± 0.0500.080 ± 0.034
SecondaryPharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin Concentration (MCHC)
Time frame:
Baseline through 6 weeks
Reported as:
Mean · millimoles/liter of iron (mml/L-Fe)
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin Concentration (MCHC)
millimoles/liter of iron (mml/L-Fe)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Mean Corpuscular Hemoglobin Concentration (MCHC)1.4 ± 0.51.2 ± 0.41.6 ± 0.71.5 ± 0.6
SecondaryPharmacodynamics (PD): Maximum Change in Ferritin
Time frame:
Baseline through 6 weeks
Reported as:
Mean · micrograms/liter (ug/L)
Pharmacodynamics (PD): Maximum Change in Ferritin
micrograms/liter (ug/L)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Pharmacodynamics (PD): Maximum Change in Ferritin269.21 ± 112.17230.28 ± 80.08196.46 ± 90.90146.65 ± 48.05
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of LY2928057

Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2 days (d), 4d, 7d, 9d, 11d postdose; Time frame for Cycle 3: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d, 14d postdose

Time frame:
Cycle 1: Predose, end of infusion, 2hours(h), 4h, 2d, 4d, 7d, 9d, 11d postdose;
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of LY2928057
micrograms per milliliter (µg/mL)300 mg LY2928057600 mg LY29280571000 mg LY2928057
Cycle 1 (First dose)67.3 ± 25274 ± 104312 ± 21
Cycle 2 (Second dose)70.0 ± 21213 ± 49397 ± 30
Cycle 3 (Third dose)62.8 ± 21177 ± 34358 ± NA
SecondaryPharmacokinetics: Area Under the Concentration Curve From Time Zero to Infinity (AUC[0-inf]) of LY2928057

Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d postdose; Time frame for Cycle 3: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d, 14d postdose;

Time frame:
Cycle 1: Predose, end of infusion, 2hours(h), 4h, 2d, 4d, 7d, 9d, 11d postdose
Reported as:
Geometric mean · micrograms x hours/milliliter(µg*h/mL)
Pharmacokinetics: Area Under the Concentration Curve From Time Zero to Infinity (AUC[0-inf]) of LY2928057
micrograms x hours/milliliter(µg*h/mL)300 mg LY2928057600 mg LY29280571000 mg LY2928057
Cycle 1 (First dose)1560 ± 397340 ± 3311200 ± 24
Cycle 2 (Second dose)1640 ± 426970 ± 4016100 ± 31
Cycle 3 (Third dose)1520 ± 406520 ± 2512000 ± NA
SecondaryNumber of Participants With Anti-LY2928057 Antibodies
Time frame:
Baseline through 84 days
Reported as:
Number · participants
Number of Participants With Anti-LY2928057 Antibodies
participantsPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
Number of Participants With Anti-LY2928057 Antibodies1463
SecondaryArea Under the Plasma Concentration-Time Curve From 0 to 336 Hours AUC(0-336) During and Outside Dialysis

Time frame for Cycle 2: Predose, end of infusion, prior to end of dialysis or 2h, post dialysis or 4h, 2d, 4d, 7d, 9d, 11d postdose; Dialysis did not occur in cycle 1.

Time frame:
Cycle 1: Predose, end of infusion, 2hours, 4h, 2d, 4d, 7d, 9d, 11d postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-Time Curve From 0 to 336 Hours AUC(0-336) During and Outside Dialysis
hr*ng/mL300 mg LY2928057600 mg LY2928057
Cycle 1 (First dose, no dialysis)1550 ± 397320 ± 33
Cycle 2 (Second dose during dialysis)1630 ± 426940 ± 40

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/7 (0%)7/7 (100%)
300 mg LY2928057—2/6 (33.3%)6/6 (100%)
600 mg LY2928057—0/11 (0%)8/11 (72.7%)
1000 mg LY2928057—1/4 (25%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
AnaemiaBlood and lymphatic system disorders0/72/60/110/4
HypertensionVascular disorders0/72/60/110/4
PneumoniaInfections and infestations0/70/60/111/4
SyncopeNervous system disorders0/71/60/111/4
Staphylococcal bacteraemiaInfections and infestations0/71/60/110/4
Ankle fractureInjury, poisoning and procedural complications0/71/60/110/4
FallInjury, poisoning and procedural complications0/71/60/110/4
HypoxiaRespiratory, thoracic and mediastinal disorders0/71/60/110/4
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo300 mg LY2928057600 mg LY29280571000 mg LY2928057
AnaemiaBlood and lymphatic system disorders5/72/63/112/4
FatigueGeneral disorders1/72/60/110/4
ConstipationGastrointestinal disorders0/70/61/111/4
Chest painGeneral disorders0/70/60/111/4
InsomniaPsychiatric disorders0/70/60/111/4
DizzinessNervous system disorders0/71/62/110/4
ToothacheGastrointestinal disorders0/71/60/110/4
BronchitisInfections and infestations0/71/60/110/4
PharyngitisInfections and infestations0/71/60/110/4
ContusionInjury, poisoning and procedural complications0/71/60/110/4

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057Total
Mean52.1 ± 9.152.5 ± 4.152.5 ± 7.661.0 ± 9.853.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057Total
Female22329
Male548219
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057Total
Hispanic or Latino10203
Not Hispanic or Latino669425
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American457319
White31419
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo300 mg LY2928057600 mg LY29280571000 mg LY2928057Total
United States7611428
08

Study locations

4 sites
  • Davita Clinical Research, DN
    Lakewood, Colorado 80228, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32806, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Davita Clinical Research
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948. doi: 10.1111/bcp.13877. Epub 2019 Mar 4. PubMed 30677788 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01991483
Lead sponsor
Eli Lilly and Company
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Dec 2013
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Feb 7, 2019
Last update
Mar 7, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Renal Insufficiency, Chronic →

Other studies from this sponsor

Eli Lilly and Company →

Start the discussion